---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-22-000030"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:47:16.361616+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prothena Q2 2022 net loss $41.2M vs net income $27.6M a year ago; cash $510.1M

## Summary
- Net loss of $41.2M ($0.88 loss per share) vs net income of $27.6M ($0.58 diluted EPS) in Q2 2021.
- Total revenue $1.3M from BMS collaboration, down from $60.1M in Q2 2021 which included Roche revenue.
- Cash and restricted cash $510.1M at June 30, 2022; no debt.
- FDA Fast Track granted for PRX012 (anti-Aβ antibody for Alzheimer's); topline Phase 1 data for PRX005 expected by year-end 2022.
- Full-year 2022 net cash used in operations and investing expected $120-$132M; year-end cash ~$454M.

## SEC filing metadata
- accession: 0001559053-22-000030
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000030/0001559053-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000030/prta-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-22-000030
- JSON: https://secwatch.observer/filing/0001559053-22-000030.json
- Plain text: https://secwatch.observer/filing/0001559053-22-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.